Carnegie Investment Counsel Raises Position in Abbott Laboratories $ABT

Carnegie Investment Counsel raised its position in shares of Abbott Laboratories (NYSE:ABT) by 6.5% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 339,644 shares of the healthcare product maker’s stock after purchasing an additional 20,846 shares during the period. Carnegie Investment Counsel’s holdings in Abbott Laboratories were worth $33,452,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SFE Investment Counsel raised its holdings in Abbott Laboratories by 6.8% in the first quarter. SFE Investment Counsel now owns 81,738 shares of the healthcare product maker’s stock worth $8,392,000 after buying an additional 5,238 shares during the last quarter. UNIVEST FINANCIAL Corp increased its position in Abbott Laboratories by 24.9% during the first quarter. UNIVEST FINANCIAL Corp now owns 29,397 shares of the healthcare product maker’s stock valued at $3,018,000 after acquiring an additional 5,863 shares during the last quarter. Fifth Third Bancorp lifted its stake in shares of Abbott Laboratories by 49.1% in the 1st quarter. Fifth Third Bancorp now owns 1,906,560 shares of the healthcare product maker’s stock worth $195,746,000 after purchasing an additional 628,021 shares during the period. Glass Wealth Management Co LLC grew its position in Abbott Laboratories by 9.7% during the first quarter. Glass Wealth Management Co LLC now owns 2,815 shares of the healthcare product maker’s stock valued at $289,000 after buying an additional 250 shares during the period. Finally, Summit Financial Strategies Inc. increased its holdings in Abbott Laboratories by 16.1% during the first quarter. Summit Financial Strategies Inc. now owns 9,465 shares of the healthcare product maker’s stock valued at $972,000 after buying an additional 1,312 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Abbott Laboratories stock traded down $0.42 during mid-day trading on Friday, hitting $93.97. The stock had a trading volume of 6,911,805 shares, compared to its average volume of 12,569,929. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $163.69 billion, a P/E ratio of 26.32, a P/E/G ratio of 1.62 and a beta of 0.61. The firm’s 50 day moving average is $89.21 and its 200 day moving average is $103.24.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ABT shares. Evercore dropped their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Oppenheimer lowered their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Citigroup cut their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. Argus decreased their price objective on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Finally, Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research report on Wednesday, April 22nd. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.42.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.